Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Xalkori“
Suchtreffer
Begriffe & Kennungen
Xalkori · 4.8 · Nervous system effects Adult patients with NSCLC All-causality neuropathy, as defined in Table 9, was experien
Eintrag öffnenXalkori · 4.8 · Neutropenia and leukopenia Complete blood counts including differential white blood cell counts should be moni
Eintrag öffnenXalkori · 4.8 · Paediatric patients ILD/pneumonitis was reported in clinical studies with crizotinib in paediatric patients wi
Eintrag öffnenXalkori · 4.8 · Paediatric patients In clinical studies with crizotinib in 110 paediatric patients with a variety of tumour ty
Eintrag öffnenXalkori · 4.8 · Paediatric patients In clinical studies with crizotinib in 110 paediatric patients with a variety of tumour ty
Eintrag öffnenXalkori · 4.8 · Paediatric patients In clinical studies with crizotinib in 110 paediatric patients with a variety of tumour ty
Eintrag öffnenXalkori · 4.8 · Paediatric patients In clinical studies with crizotinib in 110 paediatric patients with a variety of tumour ty
Eintrag öffnenXalkori · 4.8 · Paediatric patients In clinical studies with crizotinib in 110 paediatric patients with a variety of tumour ty
Eintrag öffnenXalkori · 4.8 · Paediatric patients In clinical studies with crizotinib in 110 paediatric patients with a variety of tumour ty
Eintrag öffnenXalkori · 4.8 · Paediatric patients In clinical trials, vomiting (77%), diarrhoea (69%), nausea (71%), abdominal pain (43%) an
Eintrag öffnenXalkori · 4.8 · QT interval prolongation QT prolongation can result in arrhythmias and is a risk factor for sudden death. QT p
Eintrag öffnenXalkori · 4.8 · Renal cyst Periodic monitoring with imaging and urinalysis should be considered in patients who develop renal
Eintrag öffnenXalkori · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenXalkori · 4.8 · Summary of the safety profile in adult patients with ALK-positive or ROS1-positive advanced NSCLC
Eintrag öffnenXalkori · 4.8 · Summary of the safety profile in paediatric patients
Eintrag öffnenXalkori · 4.8 · Table 10. Adverse reactions reported in paediatric patients (N=110) All Tumour Types (N=110) System organ clas
Eintrag öffnenXalkori · 4.8 · Table 9 presents adverse reactions reported in 1722 patients with either ALK-positive or ROS1-positive advance
Eintrag öffnenXalkori · 4.8 · Table 9. Adverse reactions reported in crizotinib clinical studies of NSCLC (N=1722) System organ class Very c
Eintrag öffnenXalkori · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenXalkori · 4.8 · The adverse reactions for paediatric patients of all tumour types listed in Table 10 are presented by system o
Eintrag öffnen